HK1152945A1 - Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection - Google Patents
Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infectionInfo
- Publication number
- HK1152945A1 HK1152945A1 HK11106976.2A HK11106976A HK1152945A1 HK 1152945 A1 HK1152945 A1 HK 1152945A1 HK 11106976 A HK11106976 A HK 11106976A HK 1152945 A1 HK1152945 A1 HK 1152945A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hcmv
- codon
- antigens
- optimized
- encoding
- Prior art date
Links
- 108091033319 polynucleotide Proteins 0.000 title abstract 2
- 102000040430 polynucleotide Human genes 0.000 title abstract 2
- 239000002157 polynucleotide Substances 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 208000024697 human cytomegalovirus infection Diseases 0.000 title 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 239000013612 plasmid Substances 0.000 abstract 3
- 108091026890 Coding region Proteins 0.000 abstract 1
- 108020004705 Codon Proteins 0.000 abstract 1
- 241000701022 Cytomegalovirus Species 0.000 abstract 1
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000005457 optimization Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43554902P | 2002-12-23 | 2002-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1152945A1 true HK1152945A1 (en) | 2012-03-16 |
Family
ID=32682258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11106976.2A HK1152945A1 (en) | 2002-12-23 | 2011-07-06 | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
Country Status (13)
Country | Link |
---|---|
US (5) | US7410795B2 (fr) |
EP (2) | EP1587816B1 (fr) |
JP (2) | JP2006511221A (fr) |
AT (1) | ATE471335T1 (fr) |
AU (1) | AU2003301148A1 (fr) |
CA (2) | CA2756797C (fr) |
DE (1) | DE60333035D1 (fr) |
DK (1) | DK2311848T3 (fr) |
ES (1) | ES2429338T3 (fr) |
HK (1) | HK1152945A1 (fr) |
PT (1) | PT2311848E (fr) |
SI (1) | SI2311848T1 (fr) |
WO (1) | WO2004058166A2 (fr) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105574B1 (en) * | 1999-03-26 | 2006-09-12 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
ES2308069T3 (es) * | 1999-03-26 | 2008-12-01 | Vical Incorporated | Composiciones adyuvantes para realzar inmunorespuestas a las vacunas polinucleotido-basadas. |
EP1575505A4 (fr) * | 2002-09-10 | 2007-01-24 | Vical Inc | Vaccins a base de polynucleotides, a optimisation en codon, contre l'infection au bacillus anthracis |
PT2311848E (pt) * | 2002-12-23 | 2013-10-03 | Vical Inc | Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano |
AU2003293195A1 (en) * | 2002-12-23 | 2004-07-29 | Vical Incorporated | Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes |
US7381422B2 (en) * | 2002-12-23 | 2008-06-03 | Vical Incorporated | Method for producing sterile polynucleotide based medicaments |
EP1607485A1 (fr) * | 2004-06-14 | 2005-12-21 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Méthode de quantification de l'isoforme VEGF121 dans un échantillon biologique. |
WO2006060723A2 (fr) * | 2004-12-03 | 2006-06-08 | Vical Incorporated | Procedes de production de copolymere sequence/particules amphiphiles |
CN1307423C (zh) * | 2005-01-08 | 2007-03-28 | 王明丽 | 重组抗原pp65包被酶标反应板的制法及ELISA检测试剂盒 |
JP2006223194A (ja) * | 2005-02-17 | 2006-08-31 | Tosoh Corp | スタニオカルシン1(STC1)mRNAの測定方法 |
WO2006104615A2 (fr) * | 2005-02-24 | 2006-10-05 | University Of Massachusetts | Acides nucleiques d'influenza, polypeptides et leurs utilisations |
EP1984505B1 (fr) | 2006-01-13 | 2019-12-25 | The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health | Il-15 et il-15r-alpha améliorées aux fins d'expression dans des cellules mammaliennes |
WO2008051285A2 (fr) | 2006-04-01 | 2008-05-02 | Medical Service Consultation International, Llc | Procédés et compositions de détection de champignons et de mycotoxines |
EP4368202A3 (fr) * | 2007-03-30 | 2024-08-21 | The Research Foundation for The State University of New York | Virus attenues utiles pour vaccins |
WO2009005917A2 (fr) * | 2007-05-29 | 2009-01-08 | Vical Incorporated | Procédés de traitement de la maladie infectieuse de la rougeole chez les mammifères |
EP2185195A2 (fr) | 2007-08-16 | 2010-05-19 | Tripep Ab | Plate-forme immunogène |
EP4218806A1 (fr) * | 2008-06-20 | 2023-08-02 | Duke University | Compositions et kits pour déclencher une réponse immunitaire |
EP2313503A4 (fr) * | 2008-08-01 | 2014-01-08 | Merck Sharp & Dohme | Polynucléotides variants pp65, ie1 et ie2 du cmvh et utilisations associées |
US20100068718A1 (en) | 2008-08-22 | 2010-03-18 | Hooper Dennis G | Methods and Compositions for Identifying Yeast |
CA2766907A1 (fr) | 2009-07-06 | 2011-01-13 | Novartis Ag | Molecules d'arn autorepliquantes et leurs utilisations |
HUE058971T2 (hu) | 2009-07-15 | 2022-09-28 | Glaxosmithkline Biologicals Sa | RSV F fehérjekészítmények és eljárások azok elõállítására |
WO2011024482A1 (fr) * | 2009-08-29 | 2011-03-03 | 株式会社バイオメッドコア | Procédé permettant de mesurer la capacité d'induire des lymphocytes t spécifiques de l'antigène |
US8962251B2 (en) | 2009-10-08 | 2015-02-24 | Medical Service Consultation International, Llc | Methods and compositions for identifying sulfur and iron modifying bacteria |
AU2010313339B2 (en) | 2009-10-30 | 2016-05-26 | The Administrators Of The Tulane Educational Fund | Peptide compositions and methods for inhibiting herpesvirus infection |
WO2011100443A1 (fr) * | 2010-02-11 | 2011-08-18 | Intelligent Medical Devices, Inc. | Oligonucléotides en rapport avec des gènes de clostridium difficile codant une toxine b. une toxine a ou une toxine binaire |
EP3449910A1 (fr) | 2010-07-06 | 2019-03-06 | GlaxoSmithKline Biologicals S.A. | Des émulsions cationiques huile-en-eau |
ES2586580T3 (es) | 2010-07-06 | 2016-10-17 | Glaxosmithkline Biologicals Sa | Inmunización de mamíferos grandes con dosis bajas de ARN |
PT2590676T (pt) | 2010-07-06 | 2016-11-04 | Glaxosmithkline Biologicals Sa | Partículas de transferência de tipo virião para moléculas de arn auto-replicante |
US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
PL2590626T3 (pl) | 2010-07-06 | 2016-04-29 | Glaxosmithkline Biologicals Sa | Liposomy z lipidami o korzystnej wartości pka do dostarczania rna |
EP2590670B1 (fr) | 2010-07-06 | 2017-08-23 | GlaxoSmithKline Biologicals SA | Procédé pour induire une réponse immunitaire par administration d'arn |
ES2938866T3 (es) | 2010-08-31 | 2023-04-17 | Glaxosmithkline Biologicals Sa | Liposomas pegilados para la administración de ARN que codifica para inmunógeno |
US9127321B2 (en) * | 2010-10-06 | 2015-09-08 | The Translational Genomics Research Institute | Method of detecting Coccidioides species |
JP2013544504A (ja) | 2010-10-11 | 2013-12-19 | ノバルティス アーゲー | 抗原送達プラットフォーム |
PL2667892T3 (pl) | 2011-01-26 | 2019-09-30 | Glaxosmithkline Biologicals Sa | Schemat szczepień przeciwko rsv |
ES2651143T3 (es) | 2011-05-13 | 2018-01-24 | Glaxosmithkline Biologicals Sa | Antígenos de F de prefusión del VRS |
DK2717893T3 (da) | 2011-06-08 | 2019-07-22 | Translate Bio Inc | Lipid nanopartikelsammensætninger og fremgangsmåder til mrna-levering |
MX350198B (es) | 2011-07-06 | 2017-08-30 | Novartis Ag | Emulsiones aceite en agua que contienen acidos nucleicos. |
CA2841047A1 (fr) | 2011-07-06 | 2013-01-10 | Novartis Ag | Compositions immunogenes et leurs utilisations |
WO2013006838A1 (fr) | 2011-07-06 | 2013-01-10 | Novartis Ag | Compositions de combinaisons immunogènes et utilisations de celles-ci |
TWI570240B (zh) | 2011-09-09 | 2017-02-11 | 默沙東公司 | 作為細胞巨大病毒疫苗之條件式複製cmv |
MX2014004214A (es) | 2011-10-11 | 2014-05-07 | Novartis Ag | Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes. |
BR122019027913B1 (pt) | 2011-11-11 | 2021-11-30 | Variation Biotechnologies, Inc | Partícula vírus-like, composição farmacêutica compreendendo a referida partícula e método para produção da mesma |
US10006096B2 (en) | 2012-03-27 | 2018-06-26 | Variation Biotechnologies Inc. | Methods for detection of anti-cytomegalovirus neutralizing antibodies |
JP2015522580A (ja) | 2012-07-06 | 2015-08-06 | ノバルティス アーゲー | 免疫学的組成物およびその使用 |
EP2872183B1 (fr) | 2012-07-11 | 2018-09-26 | The Trustees Of The University Of Pennsylvania | Thérapie génique induite par vaa s'appliquant à la dégénérescence rétinienne liée à l'x de rpgr |
EP3795694A3 (fr) | 2012-10-02 | 2021-06-23 | The General Hospital Corporation d/b/a Massachusetts General Hospital | Procédés associés à des états associés à la voie de la détection de l'adn |
CA2897752A1 (fr) | 2013-01-10 | 2014-07-17 | Novartis Ag | Compositions immunogenes comprenant un virus influenza et utilisations associees |
EP2765137A1 (fr) | 2013-02-07 | 2014-08-13 | Sanofi Pasteur | Induction d'une réponse cellulaire à réactivité croisée contre des antigènes de rhinovirus |
BR112015023737A2 (pt) | 2013-03-15 | 2017-10-24 | Applied Food Biotech Inc | polipeptídeo do receptor felino tas2r isolado (ftas2r), composição, polinucleotídeo isolado, par de iniciadores, vetor de expressão, célula hospedeira, cultura celular, oligonucleotídeo, anticorpo isolado ou um fragmento desse, método para identificar um composto que interage com um polipeptídeo do receptor felino tas2r, método para identificar um composto que modula um polipeptídeo do receptor felino tas2r, método para preparar uma composição comestível, método para formular uma composição comestível com palatabilidade intensificada, método para administrar um composto amargo a um animal que necessita desse, método para preparar uma composição comestível para controlar a palatabilidade da composição comestível para um animal, método para produzir uma composição de sabor para revestimento ou incorporação em uma composição comestível a ser administrada para um animal, e composição de sabor para revestimento ou incorporação em uma composição comestível a ser administrada para um animal |
WO2015048744A2 (fr) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucléotides codant des polypeptides de modulation immunitaire |
WO2015130584A2 (fr) | 2014-02-25 | 2015-09-03 | Merck Sharp & Dohme Corp. | Adjuvants de vaccins sous forme de nanoparticules lipidiques et systèmes d'administration d'antigènes |
WO2017011773A2 (fr) * | 2015-07-15 | 2017-01-19 | Modernatx, Inc. | Acides nucléiques à codons optimisés codant des anticorps |
US11007260B2 (en) | 2015-07-21 | 2021-05-18 | Modernatx, Inc. | Infectious disease vaccines |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
PE20181529A1 (es) | 2015-10-22 | 2018-09-26 | Modernatx Inc | Vacunas de acido nucleico para el virus varicela-zoster (vzv) |
WO2017070624A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins contre des maladies tropicales |
EP3364981A4 (fr) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | Vaccin contre le cytomégalovirus humain |
WO2017070616A2 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccins contre les maladies sexuellement transmissibles |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
RU2764920C2 (ru) | 2016-07-08 | 2022-01-24 | Зе Трастис Оф Зе Юниверсити Оф Пенсильвания | Способы и композиции для лечения нарушений и заболеваний, связанных с rdh12 |
WO2018075980A1 (fr) * | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Vaccin contre le cytomégalovirus humain |
US20190314486A1 (en) | 2016-10-21 | 2019-10-17 | Merck Sharp & Dohme Corp. | Influenza hemagglutinin protein vaccines |
EP3538146A4 (fr) | 2016-11-11 | 2020-07-15 | ModernaTX, Inc. | Vaccin antigrippal |
EP3551193A4 (fr) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | Vaccins à acide nucléique contre des virus respiratoires |
EP3582790A4 (fr) | 2017-02-16 | 2020-11-25 | ModernaTX, Inc. | Compositions immunogènes très puissantes |
US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
EP3595713A4 (fr) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | Vaccin contre le virus respiratoire syncytial |
US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
EP3624856B1 (fr) | 2017-05-17 | 2024-04-03 | The General Hospital Corporation | Thérapie génique contre la sclérose tubéreuse |
MX2019015076A (es) | 2017-06-15 | 2020-08-03 | Infectious Disease Res Inst | Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos. |
US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
MA54676A (fr) | 2018-01-29 | 2021-11-17 | Modernatx Inc | Vaccins à base d'arn contre le vrs |
KR20200115567A (ko) | 2018-01-29 | 2020-10-07 | 머크 샤프 앤드 돔 코포레이션 | 안정화된 rsv f 단백질 및 그의 용도 |
CN109082413B (zh) * | 2018-09-18 | 2023-01-10 | 四川安可瑞新材料技术有限公司 | 抗人IgG单克隆抗体、其杂交瘤细胞株及应用 |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
WO2020190750A1 (fr) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Vaccins à base d'arn contre le vih |
WO2021163002A1 (fr) | 2020-02-14 | 2021-08-19 | Merck Sharp & Dohme Corp. | Vaccin anti-hpv |
WO2021222222A1 (fr) | 2020-04-27 | 2021-11-04 | Mccray Jr Paul B | Compositions et procédés pour le traitement de la fibrose kystique |
EP4146797A1 (fr) | 2020-05-06 | 2023-03-15 | Orchard Therapeutics (Europe) Limited | Traitement pour les maladies neurodégénératives |
TW202413391A (zh) | 2020-06-21 | 2024-04-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白B(gB)多肽 |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
EP4208195A1 (fr) | 2020-09-04 | 2023-07-12 | Access to Advanced Health Institute | Technologie de vaccin hybride à arn atténué vivant |
US20230310569A1 (en) | 2020-09-04 | 2023-10-05 | Access To Advanced Health Institute | Genetically-adjuvanted rna vaccines |
US20230310323A1 (en) | 2020-09-04 | 2023-10-05 | Access To Advanced Health Institute | Co-lyophilized rna and nanostructured lipid carrier |
TW202245835A (zh) | 2021-02-04 | 2022-12-01 | 美商默沙東有限責任公司 | 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物 |
WO2022221736A2 (fr) | 2021-04-16 | 2022-10-20 | Genentech, Inc. | Ligands tlr7 optimisés et leurs utilisations |
WO2022266113A1 (fr) | 2021-06-14 | 2022-12-22 | Bridgebio Gene Therapy Research, Inc. | Thérapie génique contre la sclérose tubéreuse |
JP2024530050A (ja) | 2021-08-11 | 2024-08-14 | キングス・カレッジ・ロンドン | 中枢神経系に影響を及ぼす障害の改善された治療のための組成物及び方法 |
WO2023023152A1 (fr) | 2021-08-19 | 2023-02-23 | Merck Sharp & Dohme Llc | Nanoparticule lipidique thermostable et ses méthodes d'utilisation |
WO2023228116A1 (fr) | 2022-05-24 | 2023-11-30 | Access To Advanced Health Institute | Administration intranasale de vaccins à arn thermostables |
WO2024052882A1 (fr) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Composition de vaccin immunogène incorporant une saponine |
WO2024068898A1 (fr) | 2022-09-30 | 2024-04-04 | Centre National De La Recherche Scientifique | Thérapie par trans-épissage d'arn pré-messagers opa1 pour le traitement de maladies associées à des mutations du gène opa1 |
WO2024147114A1 (fr) | 2023-01-06 | 2024-07-11 | Bloomsbury Genetic Therapies Limited | Compositions et procédés pour le traitement de la maladie de parkinson |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6100064A (en) | 1984-04-06 | 2000-08-08 | Chiron Corporation | Secreted viral proteins useful for vaccines and diagnostics |
US6242567B1 (en) * | 1984-07-27 | 2001-06-05 | City Of Hope | Method for detection and prevention of human cytomegalovirus infection |
US6133433A (en) | 1984-07-27 | 2000-10-17 | City Of Hope | Method for detection and prevention of human cytomegalovirus infection |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (fr) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Récepteurs chimériques par liaison et expression de l'ADN |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
WO1987002671A1 (fr) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Assemblage modulaire de genes d'anticorps, anticorps ainsi prepares et utilisation |
US6162620A (en) * | 1986-03-07 | 2000-12-19 | Cogent Limited | Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor |
US5124440A (en) * | 1986-11-24 | 1992-06-23 | The Childrens Hospital, Inc. | Antibody and T cell recognition sites on glycoproteins comprising the GCI complex of human cytomegalovirus |
US5547834A (en) * | 1988-01-29 | 1996-08-20 | Chiron Corporation | Recombinant CMV neutralizing proteins |
WO1989007143A1 (fr) | 1988-01-29 | 1989-08-10 | Chiron Corporation | Proteines recombinantes de neutralisation de cmv |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US6174666B1 (en) * | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
US5795737A (en) * | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
US5656611A (en) | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
US5885971A (en) | 1995-03-24 | 1999-03-23 | The Regents Of The University Of California | Gene therapy by secretory gland expression |
US5837693A (en) | 1995-03-24 | 1998-11-17 | The Regents Of The University Of California | Intravenous hormone polypeptide delivery by salivary gland expression |
US5721354A (en) * | 1995-03-31 | 1998-02-24 | Aviron | Human cytomegalovirus DNA sequences |
US5800981A (en) * | 1996-02-22 | 1998-09-01 | University Of Limburg | Human cytomegalovirus antigen and its use |
US6020481A (en) | 1996-04-01 | 2000-02-01 | The Perkin-Elmer Corporation | Asymmetric benzoxanthene dyes |
US6448389B1 (en) * | 1996-04-23 | 2002-09-10 | The Wistar Institute Of Anatomy And Biology | Human cytomegalovirus DNA constructs and uses therefor |
FR2753512B1 (fr) * | 1996-09-19 | 1998-12-31 | Sachs Ind Sa | Chaine de transmission notamment pour cycle |
US6074645A (en) * | 1996-11-12 | 2000-06-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
US6156317A (en) * | 1996-11-12 | 2000-12-05 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
WO1999002694A1 (fr) | 1997-07-09 | 1999-01-21 | The University Of Queensland | Sequence d'acides nucleiques et procede pour exprimer, de maniere selective, une proteine dans une cellule ou un tissu cible |
KR100239879B1 (ko) * | 1997-11-05 | 2000-02-01 | 김상조 | 간암 예방 및 치료용 생약제 |
JP3253590B2 (ja) * | 1998-08-31 | 2002-02-04 | シャープ株式会社 | ハーフトーンマスクの製造方法 |
ES2308069T3 (es) | 1999-03-26 | 2008-12-01 | Vical Incorporated | Composiciones adyuvantes para realzar inmunorespuestas a las vacunas polinucleotido-basadas. |
FR2804028B1 (fr) * | 2000-01-21 | 2004-06-04 | Merial Sas | Vaccins adn ameliores pour animaux de rente |
US6835383B2 (en) * | 2000-03-23 | 2004-12-28 | City Of Hope | Protein kinase deficient, immunologically active CMVpp65 mutants |
WO2001080897A2 (fr) | 2000-04-21 | 2001-11-01 | Vical Incorporated | Compositions pour l'administration in vivo d'agents therapeutiques derives de polynucleotides et methodes associees |
EP1156112B1 (fr) | 2000-05-18 | 2006-03-01 | Geneart GmbH | Gènes synthétiques pour gagpol et leur utilisation |
EP1335953A4 (fr) * | 2000-06-23 | 2005-03-30 | Merck & Co Inc | Adjuvants de vaccins polynucleotidiques et formulations contenant des tensioactifs cationiques, procedes d'utilisation associes |
US20020110567A1 (en) * | 2000-08-10 | 2002-08-15 | Volker Gerdts | In utero oral nucleic acid immunization |
PT2311848E (pt) | 2002-12-23 | 2013-10-03 | Vical Inc | Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano |
US20050283146A1 (en) | 2004-06-17 | 2005-12-22 | Lentz David J | Thermally extended spiral cryotip for a cryoablation catheter |
-
2003
- 2003-12-19 PT PT100062272T patent/PT2311848E/pt unknown
- 2003-12-19 DE DE60333035T patent/DE60333035D1/de not_active Expired - Lifetime
- 2003-12-19 CA CA2756797A patent/CA2756797C/fr not_active Expired - Fee Related
- 2003-12-19 ES ES10006227T patent/ES2429338T3/es not_active Expired - Lifetime
- 2003-12-19 JP JP2004563851A patent/JP2006511221A/ja active Pending
- 2003-12-19 WO PCT/US2003/040685 patent/WO2004058166A2/fr active Application Filing
- 2003-12-19 EP EP03814236A patent/EP1587816B1/fr not_active Expired - Lifetime
- 2003-12-19 CA CA2508228A patent/CA2508228C/fr not_active Expired - Fee Related
- 2003-12-19 AU AU2003301148A patent/AU2003301148A1/en not_active Abandoned
- 2003-12-19 US US10/738,986 patent/US7410795B2/en not_active Expired - Fee Related
- 2003-12-19 EP EP10006227.2A patent/EP2311848B1/fr not_active Expired - Lifetime
- 2003-12-19 AT AT03814236T patent/ATE471335T1/de not_active IP Right Cessation
- 2003-12-19 SI SI200332305T patent/SI2311848T1/sl unknown
- 2003-12-19 DK DK10006227.2T patent/DK2311848T3/da active
-
2007
- 2007-08-17 US US11/892,020 patent/US7888112B2/en not_active Expired - Fee Related
-
2010
- 2010-04-27 JP JP2010101904A patent/JP5129292B2/ja not_active Expired - Fee Related
-
2011
- 2011-01-25 US US13/013,752 patent/US8278093B2/en not_active Expired - Fee Related
- 2011-07-06 HK HK11106976.2A patent/HK1152945A1/xx not_active IP Right Cessation
-
2012
- 2012-06-18 US US13/525,814 patent/US8673317B2/en not_active Expired - Fee Related
-
2014
- 2014-02-10 US US14/176,813 patent/US9180162B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP5129292B2 (ja) | 2013-01-30 |
WO2004058166A3 (fr) | 2005-06-16 |
US8278093B2 (en) | 2012-10-02 |
CA2756797C (fr) | 2015-05-05 |
CA2508228A1 (fr) | 2004-07-15 |
DK2311848T3 (da) | 2013-10-14 |
EP1587816A4 (fr) | 2006-06-07 |
US8673317B2 (en) | 2014-03-18 |
DE60333035D1 (de) | 2010-07-29 |
US20130017217A1 (en) | 2013-01-17 |
US9180162B2 (en) | 2015-11-10 |
US20110177124A1 (en) | 2011-07-21 |
US20080085870A1 (en) | 2008-04-10 |
ATE471335T1 (de) | 2010-07-15 |
CA2508228C (fr) | 2013-12-17 |
WO2004058166A2 (fr) | 2004-07-15 |
PT2311848E (pt) | 2013-10-03 |
SI2311848T1 (sl) | 2013-11-29 |
JP2006511221A (ja) | 2006-04-06 |
EP2311848A1 (fr) | 2011-04-20 |
EP2311848B1 (fr) | 2013-07-03 |
CA2756797A1 (fr) | 2004-07-15 |
US7888112B2 (en) | 2011-02-15 |
US20140186382A1 (en) | 2014-07-03 |
US20040209241A1 (en) | 2004-10-21 |
EP1587816A2 (fr) | 2005-10-26 |
ES2429338T3 (es) | 2013-11-14 |
JP2010227101A (ja) | 2010-10-14 |
EP1587816B1 (fr) | 2010-06-16 |
US7410795B2 (en) | 2008-08-12 |
AU2003301148A8 (en) | 2004-07-22 |
AU2003301148A1 (en) | 2004-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1152945A1 (en) | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection | |
KR101650364B1 (ko) | 항원-특이적인 t 세포 반응을 유도하는 면역 강화제로서 사용을 위한 융합 단백질 | |
Drew et al. | Humoral immune responses to DNA vaccines expressing secreted, membrane bound and non-secreted forms of the: Taenia ovis 45W antigen | |
US10227385B2 (en) | Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection | |
Schneeweiss et al. | A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII | |
US20080044384A1 (en) | Recombinant Human Cytomegalovirus And Vaccines Comprising Heterologous Antigens | |
AU734443B2 (en) | Vaccines | |
CN105039266A (zh) | 复制缺陷型黄病毒疫苗和疫苗载体 | |
US20230234992A1 (en) | Modified betacoronavirus spike proteins | |
IL134341A0 (en) | Compositions for inducing an immune response containing an hpv protein antigen | |
CN109963586B (zh) | 作为抗疟疾疫苗的生物融合蛋白 | |
DK263390D0 (da) | Flagellinrekombinantgener, undeinsyrekloner, mikroorganismer, proteiner og vacciner indeholdende dem samt fremgangsmaade til deres ekspression | |
EP0538341B1 (fr) | Vaccin a base de glycoproteine de vhe-4 (virus d'herpes equin-4) | |
JP2002503251A (ja) | 単純ヘルペスウイルスvp22ワクチンおよび使用の方法 | |
ES2353134T3 (es) | Forma no escindible de la proteina gb de hcmv. | |
JP2023523423A (ja) | SARS-CoV-2に対するワクチン及びその調製物 | |
Toussaint et al. | Genetic immunisation of cattle against bovine herpesvirus 1: glycoprotein gD confers higher protection than glycoprotein gC or tegument protein VP8 | |
EP1090994B1 (fr) | Immunogènes à séquences peptidiques répétitives | |
CA3170674A1 (fr) | Nouveau vaccin a coronavirus a base de salmonella | |
KR20210140809A (ko) | 고효능 사스 코로나바이러스 2 항원 및 이를 포함하는 백신 조성물 | |
Drew et al. | A comparison of DNA vaccines expressing the 45W, 18k and 16k host-protective antigens of Taenia ovis in mice and sheep | |
CY1114437T1 (el) | Εμβολια με βαση πολυνουκλεοτιδιο βελτιστοποιημενου κωδικονιου εναντι μολυνσης ανθρωπινου κυτομεγαλοϊου | |
ES2900364T3 (es) | Glicoproteína G truncada del virus del herpes simple tipo 2 | |
WO2022055375A1 (fr) | Vaccin vivant recombinant pour le sars-cov-2 à base de salmonella enteritidis recombinante | |
KR20240053097A (ko) | 사스 코로나바이러스 2 베타 변이주 항원 및 이를 포함하는 고효능 백신 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20181219 |